Aspire Biopharma Holdings, Inc. 8-K

What Happened
Aspire Biopharma Holdings, Inc. (ASBP) filed a Form 8-K on April 16, 2026, to disclose a press release under Item 7.01 (Regulation FD Disclosure). The press release is furnished as Exhibit 99.1 and is incorporated by reference in the filing. No other substantive items (e.g., earnings, executive changes, mergers) were reported in this 8-K.

Key Details

• Filed date: April 16, 2026 (Form 8-K).
• Item reported: 7.01 — Regulation FD Disclosure; press release furnished as Exhibit 99.1.
• Exhibits listed under Item 9.01: Exhibit 99.1 (Press Release dated April 16, 2026) and Exhibit 104 (Inline XBRL cover page).
• The filing does not include Item 2.02 (earnings), Item 5.02 (executive changes), or Item 1.01 (merger) disclosures.

Why It Matters
A Regulation FD disclosure means Aspire furnished a press release to ensure material information is made publicly available to all investors at the same time. Investors should read Exhibit 99.1 (the press release) for any material updates that could affect the company’s outlook, stock price, or forthcoming filings. Because this 8-K only furnishes a press release and lists exhibits, there are no new financial statements or reported management changes in this filing.